EPISODE · Mar 7, 2022 · 55 MIN
CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
from Business Of Biotech · host Matt Pillar
We love to hear from our listeners. Send us a message. While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovarian cancers. Discover more on recent developments in autologous and allogeneic CAR T-cell therapies in this column from Mustang Bio at BioProcessOnline.com. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Embed this episode
What this episode covers
We love to hear from our listeners. Send us a message. While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovari...
Ready to play
CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.